Regarding medication, patients in the present study were treated with drugs that improved the survival of HF (SOLVD investigators et al. 1991, Packer et al. 1996, Pitt et al. 1999), but decreased TGF-β transcription, such as angiotensin-converting enzyme inhibitor (Kim et al. 1996), spirolactone (Zhou et al. 2016), and carvedilol (Wong et al. 2001). This evidence concerns the gene TGFB1 and hydrops fetalis.